Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
1998-04-28
2001-10-30
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S085200, C514S045000, C514S049000, C514S050000, C514S235500
Reexamination Certificate
active
06309632
ABSTRACT:
FIELD OF THE INVENTION
The subject invention relates to methods for reducing HIV viral load and treating AIDS by administering granulocyte-macrophage colony stimulating factor (GM-CSF).
BACKGROUND OF THE INVENTION
Patients infected with Human Immunodeficiency Virus (HIV) experience a variable but progressive decline in immune function resulting in clinically apparent opportunistic infections and other diseases. (Crowe et al.,
J. Acquir. Immune Defic. Syndr.
4:770-76, 1991; Moss et al.,
AIDS
3:55-61, 1989). The onset of severe immunodeficiency in HIV-infected individuals is generally accompanied by a marked increase in viral burden and a dramatic decline in circulating CD4
+
T-lymphocytes. Recent approaches to HIV therapy include administration of immunomodulatory agents, such as interleukin-2, with antiretroviral drugs to improve host immunity, thereby attempting to decrease opportunistic infections and prolong survival. Cytokines and growth factors may have a beneficial effect by increasing the number and function of immune system effector cells, including neutrophils, monocytes, macrophages, lymphocytes, dendritic cells, and natural killer cells; however, there is some concern that activation of lymphocytes or monocytes/macrophages may potentially increase the HIV load and produce toxicity that limits the use of these biologics. Indeed, decrease in viral burden is one of the primary clinical end-points for halting the progression of HIV infection. Accordingly, a decrease in viral load is generally regarded as an indicator of efficacy for anti-HIV drugs.
Inhibition of HIV replication can reduce viral load. Such antiretroviral therapy typically involves combinations of drugs such as protease inhibitors, nucleoside analogs, and non-nucleoside reverse transcriptase inhibitors. Other agents, including biologics, have also demonstrated some antiviral effects. The decrease in viral load is generally, but not always, associated with an increase in the number of circulating CD4
+
T-cells. (Yarchoan et al.,
Ann Intern. Med.
115:184-89, 1991; Hirsch and D'Aquila, N.
Engl. J. Med.
328:1686-95, 1993; Volberding, P. A., In: Crowe et al., eds.,
Management of the HIV
-
Infected Patient,
pp. 53-63). Unfortunately, antiretroviral drugs do not result in complete reconstitution of the immune function. Moreover, inhibition of viral replication by these agents is temporary, due to the evolution of resistant strains of virus that can grow in the presence of the antiretroviral agents. (Cameroni et al., Third Human Retroviral Conference, January 1996, Abstract #LB6a).
Growth factor cytokines such as granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and erythropoietin (EPO) have also been administered to patients with HIV. (Scadden et al., 1991, Levine et al.,
Blood
73:3148-54, 1991; Kaplan et al.,
J. Clin. Oncol.
9:929-40, 1991; Stricken and Goldberg,
Clin. Immunol. Immunopathol.
79:194-96, 1996; Miles et al.,
Blood
77:2109-17, 1991; Pluda et al.,
Hematol. Oncol. Clin. North Am.
5:22948, 1991). Recently, GM-CSF has been the subject of several studies to evaluate its ability to prevent opportunistic infections in individuals with HIV.
LEUKINE®, a yeast-derived form of GM-CSF, is currently available for use in promoting myeloid cell recovery following bone marrow transplant post-myeloablative therapy for the treatment of malignancies. An
E. coli
-derived form of GM-CSF is also available for use in promoting the recovery of neutrophils in HIV-infected patients with granulocytopenia. (Scadden et al.,
J. Clin. Oncol.
9:802-08, 1991; Levine et al., Blood 78:3148-54, 1991; Kaplan et al.,
J. Clin. Oncol.
9:929-40, 1991; Hardy et al., Eur.
J. Clin. Microbiol. Infect. Dis.
13:S34-S40, 1994). However, the widespread use of GM-CSF for treatment of HIV infection has been hindered by data from in vitro studies whose results suggest that this cytokine might actually enhance HIV replication (Bender et al.,
J. Immunol.
151:5416, 1993; Foli et al.,
Blood
8:2114, 1995; Pluda et al.,
Hematol. Oncol. Clin. North Am.
5:229-48, 1991). More recent studies have reported results which are inconsistent with earlier studies with regard to the effect of GM-CSF on HIV viral replication (Perno et al., Third Human Retroviral Conf., January 1996, Abstract #463; Pluda et al., Blood 76:463-72, 1990; Fletcher and Gasson,
Blood
71:652-58, 1988; Mitsuyasu, R. T. In: Volberding and Jacobson, eds.
AIDS Clinical Review,
N.Y., N.Y. 1993-94, pp. 189-212). It is now believed that in the presence of antiretroviral therapy, GM-CSF does not increase HIV viral replication. (Scadden et al., 1995; Davison et al.,
J. Clin. Pathol.
47:855-57, 1994, Scadden et al.,
AIDS Res. and Human Retroviruses
12:1151-59, 1996). Indeed, in vitro data have demonstrated the enhancement of AZT activity by GM-CSF due to increased intracellular concentration of the active triphosphorylated form of AZT. (Hammer and Gillis,
Antimicrob. Agents Chemother.
31:1046-50, 1987).
Developing effective therapies for HIV disease has presented a formidable challenge for medical researchers. Although significant advancements have been made in the treatment of HIV-infected patients, many patients remain untreatable due to ineffectiveness of the therapeutic drugs used or inability of the patients to tolerate the side effects of the therapies. Clearly, existing therapies do not yet offer a cure to HIV disease. Immune-modulating agents, such as GM-CSF, may therefore offer an additional alternative treatment.
SUMMARY OF THE INVENTION
The present invention is directed to the discovery that GM-CSF is capable of reducing viral load in HIV-infected patients. The present invention is therefore directed to methods for reducing HIV viral load in HIV-infected patients by the therapeutic administration of GM-CSF. This method of treatment has been demonstrated to reduce the HIV viral load in patients concurrently receiving antiretroviral drugs.
This invention is based on the results of double-blinded, placebo-controlled studies that enrolled HIV-infected patients at multiple study sites. Patients receiving anti-retroviral agents received therapeutically effective amounts of recombinant human GM-CSF or placebo. Viral load and CD4
+
T-lymphocyte counts were determined prior to the start of the study (baseline), then at intermittent periods after the start of the study. Results indicated that GM-CSF caused a clinically significant reduction in the HIV viral load in a significantly greater number of individuals.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention provides methods for reducing HIV viral load in an HIV-infected patient by administering therapeutically effective amounts of granulocyte-macrophage colony stimulating factor (GM-CSF).
In accordance with the present invention, GM-CSF is administered to HIV-infected patients in amounts and for a time sufficient to induce a significant decrease in HIV viral load. “HIV viral load” is measured by determining the level of HIV-RNA (measured in copies per ml) detectable by PCR in the plasma of an HIV-infected patient. For the purposes of the present invention, a “clinically significant” reducation in HIV viral load is defined as a reduction greater than or equal to about 0.5 log
10
relative to the baseline value.
GM-CSF used in the practice of the invention includes any pharmaceutically safe and effective human GM-CSF, or any derivative thereof having the biological activity of human GM-CSF. In a presently preferred embodiment, the GM-CSF used in the practice of the subject methods is recombinant human GM-CSF (rhu GM-CSF), such as LEUKINE® (Immunex Corporation, Seattle, Wash.). LEUKINE® is a biosynthetic, yeast-derived, recombinant human GM-CSF, consisting of a single 127 amino acid glycoprotein that differs from endogenous human GM-CSF by having a leucine instead of a proline at position 23. Other natural and synthetic GM-CSFs, and derivatives thereof having the biological activity of natural human GM
Immunex Corporation
Sheiness Diana K.
Stucker Jeffrey
Winkler Ulrike
LandOfFree
Methods for treating HIV-infected patients by administering... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating HIV-infected patients by administering..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating HIV-infected patients by administering... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2614303